MDACC Study No:2010-0708 ( NCT No: NCT01363128)
Title:Phase II Study of the Hyper - CVAD Regimen in Combination with Ofatumumab as Frontline Therapy for patients with CD-20 positive Acute Lymphoblastic Leukemia
Principal Investigator:Elias Jabbour
Treatment Agent:Cytarabine; HCVAD; Methotrexate; Ofatumumab
Study Status:Open
Study Description:The goal of this clinical research study is to learn if ofatumumab combined
with standard chemotherapy can help to control ALL. The safety of these drug
combinations will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Cytarabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:GSK
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Elias Jabbour
For Clinical Trial Enrollment:713-792-4764
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults